LONG-TERM PROGNOSTIC VALUE OF SERUM-BETA-2 MICROGLOBULIN IN MYELOMATOSIS

被引：54
作者：
CUZICK, J
DESTAVOLA, BL
COOPER, EH
CHAPMAN, C
MACLENNAN, ICM
机构：
[1] UNIV LEEDS,DIAGNOST DEV UNIT,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND
[2] UNIV BIRMINGHAM,SCH MED,DEPT IMMUNOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 1990年 / 75卷 / 04期
关键词：
D O I：
10.1111/j.1365-2141.1990.tb07790.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Summary. The prognostic value of serum β2 microglobulin (sβ2m) measured at entry, at plateau and at 3‐monthly follow‐up times has been assessed for patients in the Medical Research Council's 4th and 5th Myelomatosis Trials. Analysis of 1014 patients confirmed the value of presentation sβ2m of predicting survival in the short term but showed that predictive value was lost for subsequent survival in those patients who had survived for at least 2 years. However, measurements of sβ2m taken during follow‐up were predictive of subsequent survival. The predictive power of these follow‐up measurements was very similar to that for the presenting measurement, and again they were only of value in predicting survival in the next 2 years. Copyright © 1990, Wiley Blackwell. All rights reserved
引用
收藏
页码：506 / 510
页数：5
相关论文
共 15 条
[1]  
BATAILLE R, 1984, BLOOD, V63, P468
[2]   PROGNOSTIC FACTORS AND STAGING IN MULTIPLE-MYELOMA - A REAPPRAISAL [J].
BATAILLE, R ;
DURIE, BGM ;
GRENIER, J ;
SANY, J .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (01) :80-87
[3]   LONG-TERM SURVIVAL IN MYELOMATOSIS - A REPORT TO THE MRC WORKING PARTY ON LEUKEMIA IN ADULTS [J].
BUCKMAN, R ;
CUZICK, J ;
GALTON, DAG .
BRITISH JOURNAL OF HAEMATOLOGY, 1982, 52 (04) :589-599
[4]   EVALUATION OF SERUM BETA-2-MICROGLOBULIN AS A PROGNOSTIC INDICATOR IN MYELOMATOSIS [J].
CHILD, JA ;
CRAWFORD, SM ;
NORFOLK, DR ;
OQUIGLEY, J ;
SCARFFE, JH ;
STRUTHERS, LPL .
BRITISH JOURNAL OF CANCER, 1983, 47 (01) :111-114
[5]   HIGH SERUM IL-2 LEVELS ARE PREDICTIVE OF PROLONGED SURVIVAL IN MULTIPLE-MYELOMA [J].
CIMINO, G ;
AVVISATI, G ;
AMADORI, S ;
CAVA, MC ;
GIANNARELLI, D ;
DINUCCI, GD ;
MAGLIOCCA, V ;
PETRUCCI, MT ;
POTI, G ;
SGADARI, C ;
MANDELLI, F .
BRITISH JOURNAL OF HAEMATOLOGY, 1990, 75 (03) :373-377
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]   THE PROGNOSTIC VALUE OF SERUM BETA-2 MICROGLOBULIN COMPARED WITH OTHER PRESENTATION FEATURES IN MYELOMATOSIS - (A REPORT TO THE MEDICAL-RESEARCH-COUNCILS WORKING PARTY ON LEUKEMIA IN ADULTS) [J].
CUZICK, J ;
COOPER, EH ;
MACLENNAN, ICM .
BRITISH JOURNAL OF CANCER, 1985, 52 (01) :1-6
[8]  
GREIPP PR, 1988, BLOOD, V72, P219
[9]   RESULTS OF THE MRC MYELOMATOSIS TRIALS FOR PATIENTS ENTERED SINCE 1980 [J].
MACLENNAN, ICM ;
KELLY, K ;
CROCKSON, RA ;
COOPER, EH ;
CUZICK, J ;
CHAPMAN, C .
HEMATOLOGICAL ONCOLOGY, 1988, 6 (02) :145-158
[10]   SERUM BETA-2-MICROGLOBULIN IN MYELOMATOSIS - POTENTIAL VALUE IN STRATIFICATION AND MONITORING [J].
NORFOLK, D ;
CHILD, JA ;
COOPER, EH ;
KERRUISH, S ;
WARD, AM .
BRITISH JOURNAL OF CANCER, 1980, 42 (04) :510-515
12